Treatment strategies for relapsed/refractory AML are limited and disappointing. Recently, high-dose melphalan (HDM) chemotherapy and autologous hematopoietic SCT (HSCT) has been proposed for AML re-induction. We investigated the impact of HDM remission induction in highly advanced relapsed/refractory AML patients planned for allogeneic HSCT. A total of 23 patients with relapsed/ refractory AML were prospectively scheduled for HDM with or without stem cell support followed by myeloablative allogeneic HSCT. Patients included nine individuals with a history of previous HSCT (seven allogeneic, two autologous). A total of 18 patients (78%) achieved a leukemiafree state and an additional four had substantial reduction of the initial leukemia burden warranting treatment continuation. There were no differences between patients with or without immediate stem cell support regarding mucositis or other organ toxicity. A total of 20 patients proceeded to myeloablative allogeneic HSCT. Outcome of allogeneic HSCT was poor: 11 patients (55%) relapsed, 7 patients (35%) died from TRM and only 2 patients (10%) were alive at the last follow-up. Our study shows that HDM is effective in inducing a leukemia-free state in patients with highly advanced relapsed/refractory AML. Leukemia burden reduction with HDM, however, did not translate into improved OS.
Introduction
Relapsed and/or refractory AML has an unsatisfactory prognosis and the therapeutic options are limited. Myeloablative allogeneic hematopoietic SCT (HSCT) may be used, however, its outcome is poor compared with patients treated in remission, 1 and the optimal pre-transplant conditioning regimen still remains controversial. Melphalan is a bifunctional alkylator that exerts non-cell cycle-specific cytotoxicity, 2 has a defined toxicity profile, 3 is well tolerated and has shown promising activity in patients with relapsed/refractory AML. 4 In patients transplanted in first CR of childhood AML, high-dose melphalan (HDM) showed a similar efficacy to other preparative regimens, such as TBI and BU-based conditioning. 5 In a dose-finding study in adult patients, melphalan induced a CR in 75% of cases with relapsed/ refractory acute leukemia when given at a minimal dose of 140 mg/m 2 . 6 In another pilot study, HDM followed by allogeneic peripheral blood-related or unrelated HSCT was evaluated in the context of early relapse of AML, ALL, biphenotypic leukemia and chronic myelogenous leukemia in blast crisis. Transient remissions were observed, engraftment of both related and unrelated stem cells was assured, but no durable remissions were achieved. 7 Recently, Bug et al. proposed HDM re-induction chemotherapy and autologous stem cell support for patients with AML in first relapse. This trial proved that a large proportion of second CRs can be obtained without excessive treatment-related mortality. 8 Few data exist on the impact of HDM remission induction in AML patients planned for allo-HSCT. We analyzed the impact of HDM with and without stem cell support in even more advanced relapsed/refractory AML patients planned for myeloablative allogeneic HSCT.
Patients and methods

Patients
Patients with relapsed or refractory AML were eligible. Ethics committee approved the treatment protocols of this single-center study and all patients gave informed consent to the treatment and analysis of outcome data.
From March 2005 to April 2009, 12 males and 11 females aged 21-69 years (median 39 years) received HDM with or without stem cell support. In patients who had previously achieved a CR, the median remission duration was 6.5 months (range 2-22). The time from initial diagnosis to melphalan administration ranged from 2 to 24 months (median 8 months). All patients had highly advanced AML: seven were in primary induction failure, seven in untreated first relapse, four refractory to salvage chemotherapy and five were in second relapse. Previous allogeneic and autologous HSCT had been carried out in seven and two patients, respectively. Median blast cell percentage in the BM at the time of melphalan administration was 30% (range 5-90%, the patient with 5% marrow blasts having histologically proven leukemic infiltration of the skin). Patient and disease characteristics are summarized in Table 1 .
Treatment plan
Part 1: The re-induction regimen consisted of a single dose of melphalan 200 mg/m 2 administered i.v. On the basis of a previous trial, in which we could show that a double allogeneic HSCT is feasible with acceptable TRM, 9 double HSCT was administered when possible (group 1; n ¼ 12). Patients for whom a cryopreserved autologous hematopoietic stem cell product was available received autologous HSCT on day 0 (n ¼ 3). Patients with an HLA-identical sibling donor were allocated to tandem allo-HSCT and received a first CD34-selected graft from their sibling donor on day 0 (n ¼ 8). One patient relapsing after haploidentical HSCT and scheduled for unrelated HSCT was provided with HSCT from his previous haploidentical donor. A total of 7 out of the 12 patients in this group received in all a total of three allogeneic HSCTs, that is, one allo-HSCT in the earlier history then a tandem allo-HSCT in our protocol. All other patients had HDM without stem cell support (group 2; n ¼ 11).
Part 2: Both groups were then prospectively scheduled to undergo a second conditioning regimen 2-4 weeks after HDM consisting of CY/BU or CY/12 Gy TBI ± etoposide followed by allo-HSCT from a matched related, mismatched related or cord blood donor (Figure 1 ).
Clinical endpoints
The primary endpoints were achievement of a leukemiafree state after HDM and ability to proceed to allogeneic myeloablative HSCT. A morphologic leukemia-free state was defined according to Cheson et al. as less than 5% blasts, no blasts with Auer rods in BM samples and the absence of extramedullary disease. 10 Secondary endpoints were the toxicity profile of melphalan re-induction, as well as its feasibility and the outcome and toxicity of treatment administered after successful HDM re-induction. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Statistical analysis
Overall and PFSs were calculated by Kaplan-Meier analysis. Cumulative incidences of relapse incidence and TRM were calculated by treating these events as competing outcomes. High-dose melphalan in advanced AML
Results
Melphalan efficacy
After HDM, 78% of patients were leukemia-free as defined above (75% in the group with stem cell support and 82% in the group without). All seven patients with primary induction failure, who had been refractory to a median of two previous chemotherapy cycles, were leukemia-free after HDM. Of the five patients who did not achieve complete blast clearance, four had a substantial reduction of the initial leukemia burden warranting continuation of treatment with myeloablative allo-HSCT. More precisely, initial BM infiltration of 90, 70, 30 and 15% plus circulating blasts dropped to scarce BM blasts in the first two patients (not quantified in hypoplastic marrow) and under 10% BM blast infiltration with no evidence of extramedullary disease in the last two patients.
As for the fifth patient (patient 22), with initial BM blasts of 490% plus circulating leukemic cells, did not respond to HDM; she was, therefore, excluded from further treatment. Patient characteristics and outcome are summarized in Table 2 .
Melphalan toxicity
Infectious complications were frequent: neutropenic fever developed in all patients. Blood cultures revealed an underlying Escherichia. coli infection in two cases and Streptococcus mitis infection in three patients. In two subjects, central venous line infection was found. Pulmonary aspergillosis developed in one patient and progressed in three other patients during melphalan-induced aplasia. One patient (patient 17) presented pneumonitis due to combined CMV/respiratory syncytial virus infection, precluding further intensive treatment. There were no differences between patients with (group 1 High-dose melphalan in advanced AMLlymphoma may have contributed to lung injury in this case. The two patients excluded from further therapy because of toxicity were both in the group treated without stem cell support administered after melphalan.
Transplant outcome
A total of 20 out of 23 (87%) patients proceeded to myeloablative conditioning and allo-HSCT, according to their initial treatment plan. The remaining patients were excluded because of the non-response (n ¼ 1) and nonhematological toxicity (n ¼ 2) as described above. Conditioning was BU/CY in 8 patients, CY/TBI ± etoposide in 12 patients. Stem cell source was cord blood in 1 and peripheral blood in 19 patients. Donors were HLAidentical siblings in nine patients, unrelated donors in nine patients and HLA-haploidentical parents in two patients. The median interval between melphalan administration and conditioning for allo-HSCT was 25 days in the group that received stem cell rescue and 16 days after HDM without stem cell support. All but one of the patients who had received stem cell rescue after HDM had reconstituted peripheral blood values at the time of second conditioning, whereas only one patient had hematological recovery without stem cell support.
Neutrophil engraftment after myeloablative transplantation was reached in a median of 13 days (range 9-28) in all 18 evaluable patients. One month post transplant chimerism was 100% donor type in all patients evaluable. Acute GvHD of grade 2 was diagnosed in seven patients (39%) and of grade three in two patients (11%). Out of the six patients evaluable for chronic GvHD, limited and extensive severity were determined in one and two patients, respectively.
At last follow up, two patients were alive and in remission. Seven patients had died from TRM (infection n ¼ 2, gastrointestinal bleeding n ¼ 1, intracerebral hemorrhage n ¼ 1, veno-occlusive disease n ¼ 2, interstitial pneumonitis n ¼ 1) at a median of 32 days (range 1-67) after undergoing allogeneic HSCT. Eleven patients, relapsing in 84 days median (range 42-1019) after allo-HSCT, were subsequently treated with best supportive care (Figure 2b ). Median PFS was 74 days and median OS 79 days after the last HSCT. Analysis of predictors of PFS indicated that CR1 duration was associated with outcome after treatment: the three patients who had benefited from an initial CR1 duration 412 months invariably showed the longest PFS. The low survival frequency precluded any further analysis of predictors of transplant outcome.
Moreover, TRM rates were 36% in the group treated with HDM followed by HSCT (group 1) and 33% in the group treated with HDM without HSCT (group 2). Median OS after HDM was 107 days (Figure 2a) . No difference in survival between patients treated with or without stem cell support after high dose melphalan re-induction was seen (median 109 and 100 days, P ¼ 0.41).
Discussion
Our data confirm that HDM can induce a complete blast clearance without causing severe toxicity in a substantial proportion of AML patients with highly advanced disease. A total of 18 out of 23 patients were leukemia-free, another 4 patients achieved a significant reduction of leukemic burden after HDM. The probability of obtaining a blastfree condition was equivalent to the results achieved with HDM in patients with less advanced disease and compares favorably with other salvage regimens. 8, 4 Fatal toxicities of HDM without consecutive stem cell support have previously been reported. 11 In this trial, two patients who received HDM without HSCT were excluded from further therapy because of non-hematological adverse events. Neither during HDM-induced aplasia nor following myeloablative conditioning could other differences in toxicity between group 1 and 2 be noted. Median OS after HDM was comparable in the groups treated with and without stem cell support between HDM and myeloablative allogeneic HSCT (109 vs 100 days, respectively).
Unfortunately, the high blast clearance and feasibility of this regimen did not translate into satisfactory overall after HDM re-induction and myeloablative allogeneic hematopoietic SCT (HSCT) for AML. Outcome after myeloablative HSCT is shown.
High-dose melphalan in advanced AMLtherapy results. The dismal outcome certainly reflects the high-risk characteristics of our patient group. A total of 15 patients were classified as poor and 7 as intermediate according to the HOVON risk group definitions at first diagnosis, 7 patients were in relapse after allo-HSCT and 2 after auto-HSCT. With only 2 out of 23 patients alive at last follow-up, our results are comparable to those achieved with direct allogeneic myeloablative transplantation in patients with refractory and relapsed AML. 12 The 3 patients who had benefited from an initial CR1 duration 412 months invariably showed the longest PFS. Thus, our long-term results are in line with similar studies and support the principle of outcome being significantly determined by the length of initial response. 13 In conclusion, our study shows that HDM with or without HSCT is effective in achieving complete blast elimination in patients with highly advanced relapsed/ refractory AML and, moreover, allows a majority of patients to proceed to allogeneic HSCT with reduced tumor burden. However, the outcome of allo-HSCT performed after melphalan re-induction was poor in this cohort and does not suggest a benefit of HDM re-induction followed by myeloablative allo-HSCT over conventional myeloablative allo-HSCT in relapsed/refractory AML.
